EANS-Adhoc: november Aktiengesellschaft / Extraordinary Income Through Extensive Waiver of Debts / Restructuring of Long-Term Repayment Agreement

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

04.01.2011

Today, november AG (ISIN: DE000A0Z24E9) succeeded in negotiating an
extensive waiver of debts with the major shareholder Camkan Invest
S.a.r.l. and a restructuring of repayment modalities of all remaining
interest-free liabilities. As a result, a waiver was achieved for two
loans totaling approx. EUR 1.376 mio. Additionally, the repayment of
one interest-free loan in the amount of TEUR 255 is suspended in 2011
and installments starting 2012 are agreed upon. For PROGEN Biotechnik
GmbH the existing interest-free loans are reduced by an amount of
TEUR 75 and for the remaining liabilities of approx. EUR 1.016 mio
the repayment modalities were improved considerably, i.e. 144 monthly
installments were negotiated. With this agreement, the total
liabilities of the november group owed to the major shareholders
Camkan Invest S.a.r.l./alpha capital management GmbH could be reduced
from approx. EUR 5.132 mio (state of Dec. 12, 2008) to now approx.
EUR 1.272 mio, owed to Camkan Invest S.a.r.l. This waiver of debts
results in extraordinary income of approx. EUR 1.451 mio which
significantly improves the equity capital by this amount.
Furthermore, the changed repayment modalities reduce short-term
liabilities considerably by converting them into long-term
liabilities. Thanks to the continuously constructive cooperation with
the major shareholder Camkan Invest S.a.r.l. in the restructuring
process another significant milestone was achieved for the financial
stabilization of the november AG and its subsidiaries.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: november Aktiengesellschaft
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Dirk Zurek
Vorstand
Tel.: +49 (0) 221 82200 520 10
E-Mail: ir@november.de

Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade